7794 results for "canc*"

in 9.08 milliseconds.

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  Whole genome sequencing of the matching blood from high risk breast cancer patients

  Dataset EGAD50000002653

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  cfmedip methylation profiling CM from plasma cfDNA of high risk breast cancer patients

  Dataset EGAD50000002654

• FGFR2b Project Biliary Tract Cancer RNA Sequencing Data

  FASTQ files of RNA Sequencing data for the FGFR2b project.

  Dataset EGAD50000002899

• Single-cell transcriptome and TCR profiles of T cells from supercentenarians

  Our previous study identified CD4 cytotoxic T lymphocytes (CD4 CTLs) as a hallmark of supercentenarians. Using single-cell immune profiling, we found that CD4 CTLs begin expanding around age 100, characterized by sequential CD27/CD28 loss without exhaustion. These cells showed strong clonal expansion and shared CDR3beta sequences with tumor-infiltrating T cells, especially from lung cancer. These findings suggest that CD4 CTLs adapt to persistent antigens and may contribute to cancer surveillance in extreme aging.

  Study JGAS000815

• Germline WES of serrated polyposis syndrome

  The serrated polyposis syndrome (SPS) is a disease with a mainly unknown inherited genetic basis characterized by the presence of multiple and/or large serrated polyps in the colon and a higher associated risk for colorectal cancer (CRC). The objective of the present study was to identify new SPS/CRC germline predisposition genes by using whole-exome sequencing in two affected SPS patients from the same family.

  Study EGAS50000000765

• SOLTI- Arianna trial

  The main hypothesis of the study is that enzalutamide induces a significant proliferative arrest in HR+/HER2-negative breast cancer falling into the PAM50 HER2-E subtype. Patient population included males or pre/post-menopausal women with advanced HR+/HER2- ABC resistant to endocrine therapy, received ENZ 160 mg/day until disease progression. Patients were assigned to different cohorts according to PAM50 intrinsic subtypes identified in the pre-treatment tumor biopsy: Cohort A included pts with HER2-E and Cohort B pts with Luminal A/B tumors. Centralized molecular assessment was done at pre-treatment and C1D15.

  Study EGAS50000001979

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  EM-seq methylation profiling MC of plasma cfDNA of high risk breast cancer patients

  Dataset EGAD50000002655

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  Plasma cfDNA WGS profiling of high risk breast cancer patients.

  Dataset EGAD50000002656

• IMMUcan BC2 cohort

  The goal of IMMUcan is to understand how the immune system interacts with tumors and how therapeutic interventions influence this interaction. This cohort includes patients with confirmed localized TNBC (stages I to III) treated with neo-adjuvant therapy Comprehensive profiling data are integrated with longitudinally collected clinical information. Cellular profiling of the same tumor samples was performed using multiplex immunofluorescence imaging, imaging mass cytometry, and H&E staining.

  Study EGAS50000001938

• Impact of Mutated CTCF DNA binding sites of Topologically associating domains on nearby Cancer Gene Regulation: A Multi-Omics Analysis

  Cutaneous squamous cell carcinoma (cSCC) is the most common lethal malignancy world-wide. Due in most part to the extremely high mutational burden (TMB) in cSCC, making sense of it’s non-coding and regulatory regional genomic variation has lagged that of other far less common cancers. This study presents the first investigation of mutations at CCCTC-binding factor binding sites (CTCFbs) of Topologically associating domains (TAD) across defined cSCC progression stages—primary non-metastatic (PNM), primary metastat-ic (PM), and lymph node metastasis (LNM).

  Study EGAS50000001686